SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
In a New Post-Hoc Analysis Based on the American Association of Clinical Endocrinologists/ACE Diabetes Algorithm Significantly More Patients Achieved Blood Sugar Goals with Initial Therapy with Merck & Co., Inc.'s Diabetes Medicine JANUMET(R) (sitagliptin/metformin HCl) Compared to Metformin Alone